Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 6, 2005, Pages 367-376

  Portier, H ^a   Brambilla, C ^b   Garre, M ^c   Paganin, F ^d   Poubeau, P ^d   Zuck, P ^e  

^a HÔPITAL DU BOCAGE   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Centre Hospitalier Sud Reunion   (France)

^e Centre Hospitalier Regional Metz Thionville   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MOXIFLOXACIN; ROXITHROMYCIN;

ADULT; ALCOHOLISM; ARTICLE; BLOOD CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; QUINOLINES; ROXITHROMYCIN;

EID: 21644455261     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-1347-1     Document Type: Article

References (27)

1. Fine MJ, Auble TE, Yealy DM, et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243-250
2. Brown PD, Lerner SA (1998) Community-acquired pneumonia. Lancet 352:1295-1302
3. Boersma WG (1999) Assessment of severity of community-acquired pneumonia. Semin Respir Infect 14:103-114
4. Diaz Fuenzalida A, Vera C, Santamarina J, et al (1999) Community-acquired pneumonia in the elderly requiring hospitalization. Clinical features and prognosis. Medicina (B Aires) 59:731-738
5. Merchant S, Mullins CD, Shih YC (2003) Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther 25:593-610
6. Agence Française de Sécurité Sanitaire des Produits de Santé (2002) Antibiothérapie par voie générale en pratique courante: infections respiratoires basses de l'adulte. Méthode générale, recommandations et argumentaire. Réactualisation 2002. http://agmed.sante.gouv.fr/htm/5/rbp/indrbp.htm. Cited 24 January 2003
7. e Conférence de consensus en thérapeutique anti-infectieuse de la Socié té de pathologie infectieuse de langue française (SPILF). Prise en charge des infections des voies respiratoires basses. Méd Mal Infect 30:565-580
8. Nightingale CH (2000) Moxifloxacin, anew antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20:245-256
9. Balfour JA, Wiseman LR (1999) Moxifloxacin. Drugs 57:363-373
10. Boswell FJ, Andrews JM, Jevons G, et al (2002) Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 50:495-502
11. Bebear CM, Renaudin H, Boudjadja A, et al (1998) In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother 42:703-704
12. Roblin PM, Hammerschlag MR (1998) In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother 42:951-952
13. Ruckdeschel G, Dalhoff A (1999) The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results. J Antimicrob Chemother 43 (Suppl B):25-29
14. Jardim JR, Rico G, de la Roza C, et al (2003) A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial. Arch Bronconeumol 39:387-393
15. Torres A, Muir JF, Corris R et al (2003) Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Europ Respir J 21:135-143
16. Finch R, Schurmann D, Collins O, et al (2002) Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746-1754
17. Hoeffken G, Meyer HP, Winter J, et al (2001) The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 95:553-564
18. Petitpretz P, Arvis P, Marel M, et al (2001) Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 119:185-195
19. Patel T, Pearl J, Williams J, et al (2000) Efficacy and safety of ten-day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respir Med 94:97-105
20. Ruiz M, Ewig S, Marcos MA, et al (1999) Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 160:397-405
21. Saldias Penafiel F, O'Brien Solar A, Gederlini Gollerino A, et al (2003) Community-acquired pneumonia requiring hospitalization in immunocompetent elderly patients: clinical features, prognostic factors and treatment. Arch Bronconeumol 39:333-340
22. Meehan TP, Chua-Reyes JM, Tate J, et al (2000) Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 117:1378-1385
23. European Agency for the Evaluation of Medicinal Products (2000) Committee for Proprietary Medicinal Products (CPMP): points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99 (27 July 2000). http://www.emea.eu.int/pdfs/human/ewp/0482/99en.pdf
24. Man I, Murphy J, Ferguson J (1999) Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother 43 (Suppl B):77-82
25. Cubeddu LX (2003) QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 10:452-457
26. Jaillon P, Morganroth J, Brumpt I, et al (1996) Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 37 (Suppl A):161-167
27. Stahlmann R, Schwabe R (1997) Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 40 (Suppl A):83-92